Seven Bridges Genomics

Seven Bridges Genomics, now operating as Velsera, provides comprehensive bioinformatics solutions that facilitate genomic analysis and healthcare research, enabling clients to streamline clinical trials and enhance drug discovery. Founded in 2009 in Cambridge, US, Seven Bridges Genomics specializes in bioinformatics. The company has completed a total of 7 deals and recently raised USD 15. 00 mn in a Series C funding round, matching its total amount raised to USD 15.

00 mn, with a current valuation of USD 128. 714 mn. The founder, Bashar Turkistani, has contributed to the company's strategic operations, while William Moss currently serves as CEO. Seven Bridges Genomics, now operating under the name Velsera, delivers a suite of end-to-end bioinformatic solutions designed to accelerate healthcare research and development.

Their primary offerings include cloud-computing infrastructure, analytic workflows, and access to extensive genomic datasets. The platform enables scientists and researchers in biopharma, healthcare, and academia to organize, explore, and analyze genomic and clinical data efficiently. This functionality allows users to streamline clinical trials, enhance drug discovery processes, and optimize biomarker identification. Customers include public and private sector researchers, particularly in the United States and Europe, who benefit from immediate access to diverse public datasets and secure data-sharing capabilities.

Seven Bridges Genomics operates on a revenue structure that includes subscription-based models and partnerships with organizations in the biopharma and healthcare sectors. Clients are typically engaged through transactional agreements that provide them access to the company’s flagship products such as the ARIA, GRAF, and RHEO platforms. These agreements may involve tiered pricing plans depending on the extent of data access and computational resources required. With a focus on B2B transactions, the company's revenue is generated by providing tailored bioinformatics solutions that facilitate advanced research capabilities for its clientele.

The revenue model underscores a commitment to delivering high-value services while meeting regulatory compliance for data security and processing. Seven Bridges Genomics plans to leverage the recent funding to enhance its product offerings and expand into new geographical markets. The company is developing new features and tools that are anticipated to launch in the next 12 months, aimed at improving data analytics capabilities for its users. Additionally, Seven Bridges is targeting further penetration into markets in Europe and Asia by the end of the upcoming fiscal year, aiming to provide tailored solutions to meet the unique demands of researchers in these regions.

Recent transactions indicate a strategic shift towards increasing their global footprint and enhancing product accessibility.